Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CCCC vs OTLK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OTLK Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–5 Matrix Metrics)

OTLK Overall Winner 6-Pillar Tally: CCCC 1 – 4 OTLK (1 Tie) Matrix Metrics: CCCC 5 – 5 OTLK

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CCCC carries a Unified Composite Score of 55.0/100 (HOLD) at $2.69 (N/M Forward P/E, -315.9% operating margin), whereas OTLK carries 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin).

  • Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. OTLK 48.6/100 HOLD), OTLK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (4781.8% vs. -315.9% operating margin) and revenue trajectory (-99.4% vs. -24.6% YoY).
  • Technical & Structure Timing Caution: CCCC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.0); meanwhile OTLK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CCCC vs OTLK
CCCC NASDAQ
C4 Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$2.69
-2.72% 1D
Market Cap $363.7M
TTM Revenue $32M
Forward P/E N/M
Beta / 30D Vol 1.43β · 67% Vol
Unified Composite Score
55.0 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.4%), weak momentum, RSI 38
RSI-14: 38.0 · SMA20: $3.08 · SMA50: $3.11
OTLK NASDAQ Head-to-Head Winner
Outlook Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.40
-4.04% 1D
Market Cap $107.1M
TTM Revenue N/A
Forward P/E 2.9x
Beta / 30D Vol 1.47β · 79% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 71.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.5%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.48 · SMA50: $0.56

6-Pillar Scorecard Institutional Category Breakdown (CCCC 1 – 4 OTLK)

Columns: Metric · CCCC · OTLK
1. Valuation Multiples OTLK
Forward P/E N/M 2.9x
Trailing P/E N/M 2.9x
PEG Ratio N/M N/M
EV / Revenue 12.0x N/M
2. Growth & Scale CCCC
Revenue Growth (YoY) -24.6% -99.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $32M N/A
Market Cap $363.7M $107.1M
3. Profitability & Quality OTLK
Gross Margin 88.8% N/A
Operating Margin -315.9% 4781.8%
Net Profit Margin -282.2% 0.0%
Return on Equity (ROE) -47.6% -3.6%
4. Balance Sheet & Cash Flow OTLK
Cash Generation (TTM) -$80M -$56M
Cash Flow Margin N/A N/A
Net Cash / Leverage $23M Net Debt (0.24x D/E) $7.2M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OTLK
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 79.8% (3rd %ile) 181.3% (55th %ile)
Put/Call OI Skew 0.09x (Call-Skewed) 0.26x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CCCC (5) vs OTLK (5)
Institutional Metric CCCC OTLK Criterion Row Edge
Market Capitalization
Scale
$363.7M $107.1M Larger Scale CCCC
Trailing P/E Ratio
Valuation
N/M 2.9x Lower Multiple OTLK
Forward P/E Ratio
Valuation
N/M 2.9x Lower Multiple OTLK
Revenue Growth (YoY)
Growth
-24.6% -99.4% Higher Growth CCCC
Operating Margin (TTM)
Profitability
-315.9% 4781.8% Higher Margin OTLK
Net Profit Margin
Profitability
-282.2% 0.0% Higher Margin OTLK
Return on Equity (ROE)
Capital Efficiency
-47.6% -3.6% Higher ROE OTLK
52-Week Range Position
Momentum
29% ($2–$5) 10% ($0–$3) Stronger Trend CCCC
Beta / 30D Volatility
Risk Regime
1.43β · 67% Vol 1.47β · 79% Vol Lower Realized Risk CCCC
Unified Institutional Score
Composite Signal
55.0 / 100 (HOLD) 48.6 / 100 (HOLD) Higher Composite CCCC
Trailing 12M Revenue (USD)
Operating Scale
$32M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
88.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 12.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($23M Net Debt (0.24x D/E)) -$56M ($7.2M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CCCC +15.93 pp
CCCC: -2.89% · OTLK: -18.82%
3M Horizon CCCC +7.62 pp
CCCC: -35.77% · OTLK: -43.39%
6M Horizon OTLK +89.52 pp
CCCC: -16.61% · OTLK: +72.91%
1Y Horizon CCCC +82.63 pp
CCCC: +9.59% · OTLK: -73.04%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CCCC Revenue OTLK Revenue CCCC Op. Margin OTLK Op. Margin Margin Leader
FY2017 N/A $0M N/A -941.4% OTLK
FY2018 N/A $0M N/A -960.1% OTLK
FY2019 N/A $10M N/A -445.6% OTLK
FY2021 $50M N/A -179.4% N/A CCCC
FY2022 $30M N/A -416.6% N/A CCCC
FY2023 $20M N/A -669.8% N/A CCCC
FY2024 $40M N/A -336.1% N/A CCCC
FY2025 $40M $0M -320.5% -4744.3% CCCC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CCCC BREAKDOWN
117d in phase · OBV DISTRIBUTION
Current IV 79.8%
IV Percentile 3rd %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CCCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OTLK BREAKDOWN
103d in phase · OBV NEUTRAL
Current IV 181.3%
IV Percentile 55th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OTLK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CCCC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $363.7M market capitalization and -315.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OTLK Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $107.1M market capitalization and 4781.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CCCC vs OTLK Key Questions & Quantitative Answers

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CCCC carries a Unified Composite Score of 55.0/100 (HOLD) at $2.69 (N/M Forward P/E, -315.9% operating margin), whereas OTLK carries 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin). Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. OTLK 48.6/100 HOLD), OTLK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (4781.8% vs. -315.9% operating margin) and revenue trajectory (-99.4% vs. -24.6% YoY). Technical & Structure Timing Caution: CCCC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.0); meanwhile OTLK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CCCC leads the Growth & Scale pillar: CCCC posts -24.6% YoY revenue growth and +0.0% YoY earnings growth on $32M TTM revenue (88.8% gross margin, -315.9% operating margin), compared with OTLK at -99.4% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 4781.8% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), CCCC cumulative revenue shifted -20.0% while OTLK shifted N/A. In operating R&D and SG&A reinvestment, CCCC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OTLK.

OTLK screens cheaper on headline valuation multiples. CCCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.0x EV/Revenue (unreported FCF margin), whereas OTLK trades at 2.9x Forward P/E, 2.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CCCC (-47.6% ROE) versus OTLK (-3.6% ROE) capital efficiency.

In options market volatility and institutional positioning, CCCC carries 79.8% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.43β · 67% Vol realized risk). By comparison, OTLK carries 181.3% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.